The usual suspects would be the CEO and CMO, TR and Dr FL in this case. Regarding "having the confirmatory trial substantially enrolled at the time of approval" I think is penance for past sins by Dr Raj. They had drugs such as Beleodaq, Marqibo, Folotyn, and Evomela get accelerated approval and they'd never start the P3 trials. Actually they started a P3 Folotyn trial and that was cancelled after a few patients were enrolled. Regarding does it worry me? I have to say not at the moment. Pozi is critical to them and it's in an unmet need so I'm sure they can crank it up soon. They did hire a SVP of Clinical Development, Lyndah Dreiling, M.D back in 2020. I assume she still there and could help in getting the ball rolling. We should find out a lot more at the next quarterly which used to happen at the end of Feb but occurred at the end of March last year.
News 
Market Data 
Discover 
